NS 1619

Drug Profile

NS 1619

Latest Information Update: 23 Jan 2007

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator NeuroSearch
  • Developer GlaxoSmithKline
  • Class Antipsychotics; Benzimidazoles; Small molecules
  • Mechanism of Action Potassium channel agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued Psychotic disorders

Most Recent Events

  • 08 Jan 2001 Profile reviewed but no significant changes made
  • 10 Sep 1998 No-Development-Reported for Psychotic disorders in Denmark (Unknown route)
  • 07 Oct 1994 Preclinical development for Psychotic disorders in Denmark (Unknown route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top